Related references
Note: Only part of the references are listed.Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors
Yohei Hisada et al.
HAEMATOLOGICA (2020)
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty The FOXTROT Randomized Clinical Trial
Jeffrey I. Weitz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
RAP GTPases and platelet integrin signaling
Lucia Stefanini et al.
PLATELETS (2019)
Does fibrin(ogen) bind to monomeric or dimeric GPVI, or not at all?
Alexandre Slater et al.
PLATELETS (2019)
Intrinsic Pathway of Coagulation and Thrombosis: Insights From Animal Models
Steven P. Grover et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans
Alexander W. Koch et al.
BLOOD (2019)
Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
S. J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy
Srikanth Nagalla et al.
TRANSFUSION MEDICINE REVIEWS (2019)
Retrospective comparison of ultrasound facilitated catheter-directed thrombolysis and systemically administered half-dose thrombolysis in treatment of pulmonary embolism
Mohsen Sharifi et al.
VASCULAR MEDICINE (2019)
Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial
Christina U. Lorentz et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab First-in-Human Healthy Volunteer Trial
Christine Voors-Pette et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Neutrophil Extracellular Traps Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis
Charlotte Thalin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Clinical significance of altered collagen-receptor functioning in platelets with emphasis on glycoprotein VI
Alan T. Nurden
BLOOD REVIEWS (2019)
Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial
Stefanie Schuepke et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials
Renato D. Lopes et al.
JAMA CARDIOLOGY (2019)
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk Insight From the STOPDAPT-2 Trial
Hirotoshi Watanabe et al.
CIRCULATION (2019)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M. F. Claassens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
Satoshi Yasuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks
Augusto Martins Lima et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Transcatheter aortic valve replacement with a focus on transcarotid: a review of the current literature
Issa Pour-Ghaz et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Genetic association between plasminogen activator inhibitor-1 rs1799889 polymorphism and venous thromboembolism: Evidence from a comprehensive meta-analysis
Guangbin Huang et al.
CLINICAL CARDIOLOGY (2019)
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke
Patrick Lyden et al.
ANNALS OF NEUROLOGY (2019)
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
Jennifer R. Brown et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
The prothrombotic state in atrial fibrillation: pathophysiological and management implications
Ahsan A. Khan et al.
CARDIOVASCULAR RESEARCH (2019)
Functional significance of the platelet immune receptors GPVI and CLEC-2
Julie Rayes et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
M. Scully et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer
Jeffrey I. Zwicker et al.
JCI INSIGHT (2019)
Atrial fibrillation in patients with end-stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation
Oliver Koenigsbruegge et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2019)
Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
Negative regulators of platelet activation and adhesion
L. Stefanini et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis
Steven P. Grover et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
The search for new antithrombotic mechanisms and therapies that may spare hemostasis
Edward F. Plow et al.
BLOOD (2018)
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Vittorio Pengo et al.
BLOOD (2018)
Mechanisms of platelet clearance and translation to improve platelet storage
M. Edward Quach et al.
BLOOD (2018)
Activated protein C, protease activated receptor 1, and neuroprotection
John H. Griffin et al.
BLOOD (2018)
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans
Kristina Busygina et al.
BLOOD (2018)
Platelet collagen receptor Glycoprotein VI-dimer recognizes fibrinogen and fibrin through their D-domains, contributing to platelet adhesion and activation during thrombus formation
I. Induruwa et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
Stuart J. Connolly et al.
LANCET (2018)
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Sonia S. Anand et al.
LANCET (2018)
Current and future antiplatelet therapies: emphasis on preserving haemostasis
James D. McFadyen et al.
NATURE REVIEWS CARDIOLOGY (2018)
PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury
Karen De Ceunynck et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
William J. Powers et al.
STROKE (2018)
Dimeric Glycoprotein VI Binds to Collagen but Not to Fibrin
Mariam Ebrahim et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016
Elias J. Dayoub et al.
JAMA INTERNAL MEDICINE (2018)
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Stephanie A. Joppa et al.
JOURNAL OF CLINICAL MEDICINE (2018)
2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis Factor XI as a Target for New Anticoagulants
Jeffrey I. Weitz et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation
Simon J. Wilson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
Pascal Vranckx et al.
LANCET (2018)
The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
Hanny Al-Samkari et al.
CANCERS (2018)
A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant
Shauna L. French et al.
BLOOD ADVANCES (2018)
Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis
Donny Hanjaya-Putra et al.
JCI INSIGHT (2018)
Platelets at the vascular interface
Wolfgang Bergmeier et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases
Katrin F. Nickel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Discovery methods of coagulation-inhibiting drugs
Antonio Gomez-Outes et al.
EXPERT OPINION ON DRUG DISCOVERY (2017)
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Carlo Patrono et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation
Lucas N. Marzec et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
Thomas A. Mavrakanas et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Fibrinolysis: from blood to the brain
R. L. Medcalf
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks
Kristell Lebozec et al.
MABS (2017)
Milestone 1: Discovery and purification of heparin
Gregory B. Lim
Nature Reviews Cardiology (2017)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
Charles V. Pollack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
J. I. Weitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding
Pancras C. Wong et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Coagulation factor and protease pathways in thrombosis and cardiovascular disease
Hugo ten Cate et al.
THROMBOSIS AND HAEMOSTASIS (2017)
New developments in anticoagulants: Past, present and future
Jeffrey I. Weitz et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Thrombotic thrombocytopenic purpura
Johanna A. Kremer Hovinga et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery?
Guillaume Taylor et al.
Journal of Trauma and Acute Care Surgery (2017)
Tumor-Derived Exosomes Induce the Formation of Neutrophil Extracellular Traps: Implications For The Establishment of Cancer-Associated Thrombosis
Ana C. Leal et al.
SCIENTIFIC REPORTS (2017)
Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies
Peter Raimondi et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?
Jenneke Leentjens et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis
Reheman Adili et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Fibrin and D-dimer bind to monomeric GPVI
Marie-Blanche Onselaer et al.
BLOOD ADVANCES (2017)
New insights into the role of adipose tissue in thrombosis
Gemma Vilahur et al.
CARDIOVASCULAR RESEARCH (2017)
Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation
Jack D. Stopa et al.
JCI INSIGHT (2017)
Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease
Paul A. Gurbel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C
John H. Griffin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Inhibition of Protein Disulfide Isomerase in Thrombosis
Roelof H. Bekendam et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2016)
Arf6 controls platelet spreading and clot retraction via integrin IIb 3 trafficking
Y. Huang et al.
BLOOD (2016)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Global Burden of Thrombosis Epidemiologic Aspects
Aaron M. Wendelboe et al.
CIRCULATION RESEARCH (2016)
Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922)
Zhaohua Zheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy
Allison P. Wheeler et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2016)
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer
Thomas J. Povsic et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
Glenn N. Levine et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
A century of heparin: past, present and future
H. C. Hemker
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Structural and functional insights into enzymes of the vitamin K cycle
J. -K. Tie et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Pharmacology of anticoagulants used in the treatment of venous thromboembolism
Edith A. Nutescu et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2016)
Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial
M. Irem Baharoglu et al.
LANCET (2016)
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
A. Michael Lincoff et al.
LANCET (2016)
Platelet Physiology
Thomas Gremmel et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2016)
The VWF-GPIb axis in ischaemic stroke: lessons from animal models
Frederik Denorme et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Tissue factor expressed by adherent cells contributes to hemodialysis-membrane thrombogenicity
Souad Lakbakbi et al.
THROMBOSIS RESEARCH (2016)
A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation
Yasin Kokoye et al.
THROMBOSIS RESEARCH (2016)
Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke
Andreas Reimann et al.
HEART INTERNATIONAL (2016)
Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura
Liang Zheng et al.
BLOOD ADVANCES (2016)
Management of bleeding in patients treated with direct oral anticoagulants
Marcel Levi
CRITICAL CARE (2016)
Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia (Reprinted from Journal of Health-System Pharmacy Residents JHPR, vol 1, issue 4, 2013)
Jonathan Bain et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2015)
Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar
Omozuanvbo Aisiku et al.
BLOOD (2015)
Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation
Elmina Mammadova-Bach et al.
BLOOD (2015)
Fibrin activates GPVI in human and mouse platelets
Osama M. Alshehri et al.
BLOOD (2015)
A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury
Ting-Ting Li et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism The SEATTLE II Study
Gregory Piazza et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2015)
Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III
Jenny Bjoerkqvist et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase inhibition and aspirin in man
S. Nylander et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Idarucizumab for Dabigatran Reversal
Charles V. Pollack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis
Paul E. Marik et al.
PLOS ONE (2015)
Venous thrombosis
Alisa S. Wolberg et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Of von Willebrand factor and platelets
Marijke Bryckaert et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Platelet function tests: a comparative review
Rita Paniccia et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2015)
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development
Francesco Franchi et al.
FUTURE CARDIOLOGY (2015)
Factor XII Regulates the Pathological Process of Thrombus Formation on Ruptured Plaques
Marijke J. E. Kuijpers et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
New Targets for Atherothrombosis
Nigel Mackman
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Factor XI Regulates Pathological Thrombus Formation on Acutely Ruptured Atherosclerotic Plaques
Maurits L. van Montfoort et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis
Richard J. Travers et al.
BLOOD (2014)
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits
Jonathan W. Yau et al.
BLOOD (2014)
Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation
Jennifer Yeung et al.
BLOOD (2014)
Shaping the platelet response to vascular injury
Timothy J. Stalker et al.
CURRENT OPINION IN HEMATOLOGY (2014)
Factor XII: a drug target for safe interference with thrombosis and inflammation
Ellinor Kenna et al.
DRUG DISCOVERY TODAY (2014)
Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage A Meta-analysis
Saurav Chatterjee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Extracorporeal Circulation Without Increasing Bleeding Risk
Magnus Larsson et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Walter N. Kernan et al.
STROKE (2014)
Cytoprotective-selective activated protein C therapy for ischaemic stroke
Laurent O. Mosnier et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis
Xi Lei et al.
THROMBOSIS AND HAEMOSTASIS (2014)
An update on type 2B von Willebrand disease
Sameh Mikhail et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
Moderate Pulmonary Embolism Treated With Thrombolysis (from the MOPETT Trial)
Mohsen Sharifi et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial
Thomas J. Povsic et al.
EUROPEAN HEART JOURNAL (2013)
Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis
Daniel Aradi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
A directional switch of integrin signalling and a new anti-thrombotic strategy
Bo Shen et al.
NATURE (2013)
Scientific considerations in the review and approval of generic enoxaparin in the United States
Sau Lee et al.
NATURE BIOTECHNOLOGY (2013)
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
Genmin Lu et al.
NATURE MEDICINE (2013)
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
John W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice
Kimberly Martinod et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity
Jennifer Yeung et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor
Jozef Bartunek et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2013)
Clinical review: Bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management
Magdalena Doktorova et al.
CRITICAL CARE (2013)
Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys
Husam S. Younis et al.
BLOOD (2012)
Parenteral Anticoagulants Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
David A. Garcia et al.
CHEST (2012)
Role of Tissue Factor in Atherothrombosis
A. Phillip Owens et al.
CURRENT ATHEROSCLEROSIS REPORTS (2012)
Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents
Reema Jasuja et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo
Marie-Luise von Bruehl et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation
Kenneth N. Ikei et al.
JOURNAL OF LIPID RESEARCH (2012)
Neutrophil extracellular traps promote deep vein thrombosis in mice
A. Brill et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor
S. Nylander et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism
Timothy A. Brighton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Pierluigi Tricoci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
David A. Morrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Aspirin for Preventing the Recurrence of Venous Thromboembolism
Cecilia Becattini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Nucleic acid scavengers inhibit thrombosis without increasing bleeding
Shashank Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Protamine neutralisation of low molecular weight heparins and their oligosaccharide components
Mette Schroeder et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2011)
Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans
Martin Ungerer et al.
CIRCULATION (2011)
Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease The Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease Trial
Stephen D. Wiviott et al.
CIRCULATION (2011)
Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes The Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2011)
Platelet receptor signaling in thrombus formation
David Stegner et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial
P. Verhamme et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
A Prospective Natural-History Study of Coronary Atherosclerosis.
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
John H. Alexander et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolization After Carotid Endarterectomy A Randomized Trial
Hugh S. Markus et al.
STROKE (2011)
Vitamin K Antagonists - Current Concepts and Challenges
Hayan Moualla et al.
THROMBOSIS RESEARCH (2011)
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
Alf-Aage R. Pettersen et al.
THROMBOSIS JOURNAL (2011)
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo
Qiufang Cheng et al.
BLOOD (2010)
Deletion of the p110β isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo
Valerie Martin et al.
BLOOD (2010)
Tolerability and Pharmacokinetics of TB-402 in Healthy Male Volunteers
Peter Verhamme et al.
CLINICAL THERAPEUTICS (2010)
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
Shinya Goto et al.
EUROPEAN HEART JOURNAL (2010)
A 2-Step Mechanism of Arterial Thrombus Formation Induced by Human Atherosclerotic Plaques
Armin J. Reininger et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeting von Willebrand factor and platelet glycoprotein Ib receptor
Christa Firbas et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2010)
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
Francesco Dentali et al.
BLOOD (2009)
A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome
Jean-Louis Vincent et al.
CRITICAL CARE MEDICINE (2009)
Venous and arterial thrombosis: Two aspects of the same disease?
Paolo Prandoni
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2009)
Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model
M. J. E. Kuijpers et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Timothy Watson et al.
LANCET (2009)
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
Gilles Montalescot et al.
LANCET (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Tissue Factor in Brain Is Not Saturated With Factor VIIa Implications for Factor VIIa Dosing in Intracerebral Hemorrhage
Maureane Hoffman et al.
STROKE (2009)
Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty
Gerhard J. Johnson et al.
THROMBOSIS AND HAEMOSTASIS (2009)
Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo
Christian Schulz et al.
BASIC RESEARCH IN CARDIOLOGY (2008)
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study
B. I. Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study
S. K. Braekkan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Triggers, targets and treatments for thrombosis
Nigel Mackman
NATURE (2008)
Glycoprotein Ibα and von Willebrand factor in primary platelet adhesion and thrombus formation:: Lessons from mutant mice
Wolfgang Bergmeier et al.
THROMBOSIS AND HAEMOSTASIS (2008)
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
Brian F. Gage et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2008)
First-in-human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers
James C. Gilbert et al.
CIRCULATION (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Platelet glycoprotein VI-related clinical defects
Jane F. Arthur et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Estimation of warfarin maintenance dose based on VKORCI (-1639 G>A) and CYP2C9 genotypes
Yusheng Zhu et al.
CLINICAL CHEMISTRY (2007)
Tissue factor around dermal vessels has bound factor VII in the absence of injury
M. Hoffman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Recombinant nematode anticoagulant protein c2 in patients with non-ST-Segment elevation acute coronary syndrome - The ANTHEM-TIMI-32 trial
Robert P. Giugliano et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
The intrinsic pathway of coagulation:: a target for treating thromboembolic disease?
D. Gailani et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology - A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
Christopher K. Dyke et al.
CIRCULATION (2006)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis
P. Prandoni et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism
L. M. Reich et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Conformation-specific blockade of the integrin GPIIb/IIIa - A novel antiplatelet strategy that selectively targets activated platelets
Meike Schwarz et al.
CIRCULATION RESEARCH (2006)
Structure and function of the platelet integrin αIIbβ3
JS Bennett
JOURNAL OF CLINICAL INVESTIGATION (2005)
Tissue-specific hemostasis in mice
N Mackman
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-analysis with estimates of risk and benefit
MB Rothberg et al.
ANNALS OF INTERNAL MEDICINE (2005)
Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation
SC Robson et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2005)
Historical analysis of PAI-I from its discovery to its potential role in cell motility and disease
C Dellas et al.
THROMBOSIS AND HAEMOSTASIS (2005)
Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice
S Grüner et al.
BLOOD (2005)
Integrins: dynamic scaffolds for adhesion and signaling in platelets
SJ Shattil et al.
BLOOD (2004)
Risk of bleeding complications with antiplatelet agents: Meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials
VL Serebruany et al.
AMERICAN JOURNAL OF HEMATOLOGY (2004)
Oral GPIIb/IIIa antagonists: What went wrong?
D Cox
CURRENT PHARMACEUTICAL DESIGN (2004)
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy
EP McFadden et al.
LANCET (2004)
Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis
A Kuliopulos et al.
LIFE SCIENCES (2003)
Platelet-collagen interaction: is GPVI the central receptor?
B Nieswandt et al.
BLOOD (2003)
Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation
L Covic et al.
NATURE MEDICINE (2002)
Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis
S Kageyama et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
The Vitamin K-dependent carboxylase
SR Presnell et al.
THROMBOSIS AND HAEMOSTASIS (2002)
Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans
FS Chow et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke
JR Toomey et al.
STROKE (2002)
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent
JM Walenga et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2002)
Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys
S Kageyama et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females
T Futatani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Noninvasive follow-up of GDC-treated saccular aneurysms by MR angiography
W Weber et al.
EUROPEAN RADIOLOGY (2001)
Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis
JR Toomey et al.
THROMBOSIS RESEARCH (2000)
Thrombin signalling and protease-activated receptors
SR Coughlin
NATURE (2000)
PAR3 is a cofactor for PAR4 activation by thrombin
M Nakanishi-Matsui et al.
NATURE (2000)
Regulation of blood coagulation
CT Esmon
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY (2000)
Share Paper
